Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Fate Therapeutics, Inc.

< Previous 1 2 Next >
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics to Present at Upcoming March Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics to Present at Upcoming September Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics to Present at Upcoming June Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics to Present at Upcoming March Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics to Present at Upcoming Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.